US Residents Only

child with PDPL playing with a ball

The effectiveness and safety of Zokinvy® were studied in clinical trials


Zokinvy adds years to young people’s lives and improves symptoms of Progeria and processing-deficient Progeroid Laminopathies (PDPL), empowering them to do more of what matters most

Zokinvy extended life by an average of 2.5 years (over the course of 11 years) in young people with Progeria or PDPL.


Young people who received Zokinvy had lower blood pressure and lower risk of heart damage.

  • The earlier Zokinvy was given, the greater the benefit*

  • Zokinvy was shown to reduce or delay the effects of many symptoms of Progeria and PDPL, including heart and bone problems.

With the chance for a longer life, your family member with Progeria or PDPL can do more than they had ever imagined.

*Zokinvy is indicated for young people 12 months of age and older.

Zokinvy has well-understood risks, and most common side effects can be successfully managed

Zokinvy has a well-studied safety and tolerability profile in young people 12 months of age and older with Progeria or PDPL.

  • In the clinical studies, young people receiving Zokinvy experienced mild to moderate diarrhea and vomiting, decreased appetite, and nausea

  • Gastrointestinal side effects can often be successfully managed with supportive care and generally decreased over time

  • Side effects occurred most often during the first month of treatment

Merlin, a young person living with Progeria Merlin, 19, USA. Photo courtesy of The Progeria Research Foundation.

Over 100 young people with Progeria or PDPL participated in clinical studies of Zokinvy; only 4 discontinued due to side effects.

Zokinvy dosage can be adjusted to manage side effects.

100+ young people treated with zokinvy
child with Progeria riding a bicycle


Do not take ZOKINVY if you are taking:

  • a strong or moderate CYP3A inhibitor or inducer
  • midazolam
  • lovastatin, simvastatin, or atorvastatin

WHAT IS ZOKINVY® (lonafarnib)?

ZOKINVY (zoh-KIN-vee) is a prescription medicine used to treat Hutchinson-Gilford Progeria Syndrome and some types of Progeroid Laminopathies known as processing-deficient Progeroid Laminopathies in young people 12 months of age and older. These illnesses are caused when the body makes harmful proteins called progerin and progerin-like proteins.